Suchergebnisse - "Motoi, Noriko"

PubPharm (269)

31

Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma

enthalten in: Frontiers in oncology | 2022

von Katsuya, Y. | Kitano, S. | Yamashita, M. | +17

32

Cytology Reporting System for Lung Cancer from the Japan Lung Cancer Society and the Japanese Society of Clinical Cytology : An Extensive Study Containing More Benign Lesions

enthalten in: Acta cytologica | 2022

von Yoshizawa, A. | Hiroshima, K. | Takenaka, A. | +17

33

The combined use of long non-coding RNA HOTAIR and polycomb group protein EZH2 as a prognostic marker of lung adenocarcinoma

enthalten in: Cancer treatment and research communications | 2022

von Iizuka, T. | Nagano, H. | Nomura, K. | +4

34

Alpha‐actinin‐4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas

enthalten in: Cancer Science | 2022

von Noro, R. | Honda, K. | Nagashima, K. | +17

35

Elastin in pulmonary pathology : relevance in tumours with a lepidic or papillary appearance. A comprehensive understanding from a morphological viewpoint

enthalten in: Histopathology | 2022

von Thunnissen, E. | Motoi, N. | Minami, Y. | +9

36

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2021

von Shirasawa, M. | Yoshida, T. | Shimoda, Y. | +18

37

Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients

enthalten in: Anticancer research | 2021

von Shimoda, Y. | Yoshida, T. | Shirasawa, M. | +11

38

Squamous differentiation in surgically resected malignant pleural mesothelioma with neoadjuvant chemotherapy

enthalten in: Pathology international | 2021

von Yotsukura, M. | Motoi, N. | Yoshida, A. | +3

39

Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2021

von Yoh, K. | Matsumoto, S. | Furuya, N. | +14

40

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

enthalten in: Scientific reports | 2021

von Morita, C. | Yoshida, T. | Shirasawa, M. | +11